Stroenie limfaticheskikh uzlov krys pri gnoynom vospalenii v regione v usloviyakh vozdeystviya interleykinom-2



如何引用文章

全文:

详细

The structure of rat lymph nodes regional to the purulent wound under the conditions of interleukin (IL-2) treatment was investigated by the methods of light microscopy. In the lymph nodes from intact animals, the cortical plateau was found to become diminished with the simultaneous paracortical zone expansion. In the regional lymph nodes from rats with an untreated purulent wound, the relative dimensions of cortical plateau were decreased because of expansion of the medullary structures. Lymphoid parenchyma and the sinuses of lymph nodes contained erythrocytes, the numbers of immuno- and plasmoblasts, macrophages and neutrophilic granulocytes were increased. IL-2 treatment in animals with a purulent inflammatory reaction secured the greater integrity of structure of these organs and of cytoarchitecture of their various zones. However, the administration of this cytokine resulted in increased vascular permeability and enhanced the probability of allergic reaction development, which requires the development and application of prophylactic measures of the specified side effects and complications.

作者简介

I MAIBORODIN

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Email: imai@mail.ru
Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Ye STREL'TSOVA

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

D YEGOROV

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

O ZARUBENKOV

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

A SHEVELA

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

S SIDOROV

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

T RODISHEVA

Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

Центр новых медицинских технологий; Научно-исследовательский институт химической биологии и фундаментальной медицины СО РАН, г. Новосибирск; Scientific Research Institute of Chemical Biology and Fundamental Medicine, RAS Siberian Branch, Novosibirsk

参考

  1. Златник Е.Ю. и Голотина Л.Ю. Применение ронколейкина для ЛАК-терапии рака яичника. Вопр. онкол., 2005, т. 51, № 6, с. 680-684.
  2. Майбородин И.В., Колмакова И.А., Притчина И.А. и Чупина В.В. Изменения десны при сочетании артериальной гипертензии с периодонтитом. Стоматология, 2005, т. 84, № 6, с. 15-19.
  3. Andre N.D., Barbosa D.S., Munhoz E. et al. Measurement of cytotoxic activity in experimental cancer. J. Clin. Lab. Anal., 2004, v. 18, № 1, p. 27-30.
  4. Balemans L.T., Mattijssen V., Steerenberg P.A. et al. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity. Cancer Immunol. Immunother., 1993, v. 37, № 1, p. 7-14.
  5. Bielawska-Pohl A., Crola C., Caignard A. et al. Human NK cells lyse organ-specific endothelial cells: analysis of adhesion and cytotoxic mechanisms. J. Immunol., 2005, v. 174, № 9, p. 5573-5582.
  6. Casley-Smith J.R. The lymphatic system in inflammation. In: The inflammatory process, 2nd ed., 1973, v. 2, p. 161-204.
  7. Collins R.A. and Oldham G. Recombinant human interleukin 2 induces proliferation and immunoglobulin secretion by bovine B-cells: tissue differences and preferential enhancement of immunoglobulin A. Vet. Immunol. Immunopathol., 1993, v. 36, № 1, p. 31-43.
  8. Dillman R.O. Lymphocyte therapy of renal cell carcinoma. Expert. Rev. Anticancer Ther., 2005, v. 5, № 6, p. 1041-1051.
  9. D'Souza W.N. and Lefrancois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol., 2003, v. 171, № 11, p. 5727-5735.
  10. Duke S.S., King L.S., Jones M.R. et al. Human recombinant interleukin 2-activated sheep lymphocytes lyse sheep pulmonary microvascular endothelial cells. Cell. Immunol., 1989, v. 122, № 1, p. 188-199.
  11. Hancock W.W., Kobzik L., Colby A.J. et al. Detection of lymphokines and lymphokine receptors in pulmonary sarcoidosis. Immunohistologic evidence that inflammatory macrophages express IL-2 receptors. Am. J. Pathol., 1986, v. 123, № 1, p. 1-8.
  12. LeBel C.P., Langlois L., Bell D.P. et al. Pharmacokinetic, pharmacodynamic, and pharmacotoxic profiles of recombinant-methionyl human interleukin-2alanine-125. (r-metHuIL-2ala125.) following intravenous and subcutaneous administration in rats. Hum. Exp. Toxicol., 1995, v. 14, № 11, p. 909-915.
  13. Maurer T. and Kimber I. Draining lymph node cell activation in guinea pigs: comparisons with the murine local lymph node assay. Toxicology., 1991, v. 69, № 2, p. 209-218.
  14. McCulloch P., Gallagher G., Walsh L.P. et al. Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cellmediated immune response. Clin. Exp. Immunol., 1991, v. 85, № 3, p. 519-524.
  15. Musiani P., Campora de E., Valitutti S. et al. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J. Biol. Response Mod., 1989, v. 8, № 6, p. 571-578.
  16. Nomura K. and Fujioka T. Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation. Nippon Hinyokika Gakkai Zasshi., 1993, v. 84, № 5, p. 831-840.
  17. Pectasides D., Varthalitis J., Kostopoulou M. et al. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in meta-static renal cell cancer. Oncology, 1998, v. 55, № 1, p. 10-15.
  18. Poudrier J. and Owens T. Th1 and Th2 help for B cells: differential capacity for induction of autonomous responsiveness to IL-2. Int. Immunol., 1995, v. 7, № 6, p. 1021-1027.
  19. Quan W.Jr., Ramirez M., Taylor C. et al. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother. Radiopharm., 2005, v. 20, № 1, p. 36-40.
  20. Spieker-Polet H., Yam P.C., Arbieva Z. et al. In vitro induction of the expression of multiple IgA isotype genes in rabbit B cells by TGF-beta and IL-2. J. Immunol., 1999, v. 162, № 9, p. 5380-5388.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2009


Периодический печатный журнал зарегистрирован как СМИ Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор): № 0110212 от 08.02.1993.
Сетевое издание зарегистрировано как СМИ Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор): ЭЛ № ФС 77 - 84733 от 10.02.2023.